A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

0301 basic medicine Immunoconjugates Lung Neoplasms [SDV.IMM] Life Sciences [q-bio]/Immunology [SDV.CAN]Life Sciences [q-bio]/Cancer Antibodies, Monoclonal, Humanized [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract Antibodies MESH: Benzodiazepinones MESH: Ipilimumab 03 medical and health sciences Clinical trials [SDV.CAN] Life Sciences [q-bio]/Cancer Monoclonal 616 Antineoplastic Combined Chemotherapy Protocols Medicine and Health Sciences MESH: Immunoconjugates Humans Antibody-drug conjugates Humanized Benzodiazepinones MESH: Humans ICTS (Institute of Clinical and Translational Sciences) Ipilimumab MESH: Lung Neoplasms 3. Good health MESH: Antineoplastic Combined Chemotherapy Protocols Nivolumab MESH: Antibodies, Monoclonal, Humanized MESH: Nivolumab [SDV.IMM]Life Sciences [q-bio]/Immunology Small-molecule agents [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract Immunotherapy Lung cancer
DOI: 10.1016/j.jtho.2021.02.022 Publication Date: 2021-02-27T12:25:52Z
ABSTRACT
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor.This includes access anonymized, individual and trial-level (analysis sets), as well other information (e.g., protocols Clinical Study Reports), long are not part of an ongoing or planned regulatory submission.This requests for trial unlicensed products indications.These can be requested by any qualified researchers who engage in rigorous, independent scientific research, will provided following review approval a research proposal Statistical Analysis Plan (SAP) execution Data Sharing Agreement (DSA).
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (15)
CITATIONS (52)